Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673178 · ClinicalTrials.gov registry record · Phase 1
Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 107
- Enrollment target
NCT01673178 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 107 participants.
The verdict
NCT01673178, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 107 participants
- Enrollment target
Study Summary
This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
Interventions
- OTHER Placebo
- DRUG 25 mg PF-05231023
- DRUG 50 mg PF-05231023
- DRUG 100 mg PF-05231023
- DRUG 150 mg PF-05231023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 107 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673178
The ClinicalTrials.gov registry entry for NCT01673178 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 107 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT01673178 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673178 about?
NCT01673178 is a clinical study titled "Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus". This is a trial in obese subjects who have poor lipid control with and without Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics of multiple doses of PF-05231023
What is the current status of trial NCT01673178?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 107 participants. The study started on 2012-10. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01673178?
The interventions under investigation include: Placebo (OTHER), 25 mg PF-05231023 (DRUG), 50 mg PF-05231023 (DRUG), 100 mg PF-05231023 (DRUG), 150 mg PF-05231023 (DRUG).
Who is sponsoring clinical trial NCT01673178?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.